Analysis of the cervical microbiome in women from the German national cervical cancer screening program.
Cervical cancer screening
Cervicovaginal microbiome
Colposcopy
HPV diagnostic
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
28
12
2022
accepted:
25
01
2023
medline:
24
7
2023
pubmed:
14
2
2023
entrez:
13
2
2023
Statut:
ppublish
Résumé
Cervical cancer (CC) is caused by a persistent high-risk human papillomavirus (hrHPV) infection. The cervico-vaginal microbiome may influence the development of (pre)cancer lesions. Aim of the study was (i) to evaluate the new CC screening program in Germany for the detection of high-grade CC precursor lesions, and (ii) to elucidate the role of the cervico-vaginal microbiome and its potential impact on cervical dysplasia. The microbiome of 310 patients referred to colposcopy was determined by amplicon sequencing and correlated with clinicopathological parameters. Most patients were referred for colposcopy due to a positive hrHPV result in two consecutive years combined with a normal PAP smear. In 2.1% of these cases, a CIN III lesion was detected. There was a significant positive association between the PAP stage and Lactobacillus vaginalis colonization and between the severity of CC precursor lesions and Ureaplasma parvum. In our cohort, the new cervical cancer screening program resulted in a low rate of additional CIN III detected. It is questionable whether these cases were only identified earlier with additional HPV testing before the appearance of cytological abnormalities, or the new screening program will truly increase the detection rate of CIN III in the long run. Colonization with U. parvum was associated with histological dysplastic lesions. Whether targeted therapy of this pathogen or optimization of the microbiome prevents dysplasia remains speculative.
Identifiants
pubmed: 36780053
doi: 10.1007/s00432-023-04599-0
pii: 10.1007/s00432-023-04599-0
pmc: PMC10356625
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6489-6500Informations de copyright
© 2023. The Author(s).
Références
Sci Rep. 2021 Sep 22;11(1):18852
pubmed: 34552145
Lancet Oncol. 2011 Jul;12(7):663-72
pubmed: 21684207
Sci Transl Med. 2012 May 2;4(132):132ra52
pubmed: 22553250
Int J Cancer. 2013 Jan 1;132(1):101-8
pubmed: 22610699
Gynecol Oncol. 2021 Nov;163(2):348-357
pubmed: 34503848
Adv Med Sci. 2011;56(2):299-303
pubmed: 21940266
BMJ. 2010 Apr 27;340:c1804
pubmed: 20423964
BJOG. 2020 Jan;127(2):171-180
pubmed: 31237400
Microbiome. 2016 Nov 1;4(1):58
pubmed: 27802830
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
J Infect Dis. 2014 Dec 1;210(11):1723-33
pubmed: 24943724
J Natl Cancer Inst. 2010 Oct 6;102(19):1478-88
pubmed: 20841605
Trends Microbiol. 2014 Jun;22(6):345-53
pubmed: 24674660
Clin Nutr. 2016 Dec;35(6):1434-1441
pubmed: 27075319
Am J Obstet Gynecol. 2001 Aug;185(2):375-9
pubmed: 11518895
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Front Microbiol. 2019 Feb 14;10:193
pubmed: 30837959
Sci Rep. 2018 Jun 26;8(1):9678
pubmed: 29946153
Nat Med. 2019 Mar;25(3):377-388
pubmed: 30842679
J Clin Virol. 2016 Mar;76 Suppl 1:S3-S13
pubmed: 26601820
N Engl J Med. 2007 Oct 18;357(16):1589-97
pubmed: 17942872
PLoS One. 2016 Apr 19;11(4):e0153553
pubmed: 27093050
Br J Cancer. 2010 Apr 27;102(9):1405-10
pubmed: 20354519
Science. 2015 Apr 3;348(6230):80-6
pubmed: 25838377
J Clin Virol. 2018 Nov;108:64-71
pubmed: 30253376
Am J Clin Pathol. 2010 Jun;133(6):894-8
pubmed: 20472847
Genomics Proteomics Bioinformatics. 2022 Apr;20(2):304-321
pubmed: 34118463
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Br J Cancer. 2003 May 19;88(10):1570-7
pubmed: 12771924
J Med Virol. 2016 Dec;88(12):2023-2024
pubmed: 27219674
Clin Infect Dis. 2003 Aug 1;37(3):319-25
pubmed: 12884154
Geburtshilfe Frauenheilkd. 2013 Sep;73(9):904-907
pubmed: 24771940
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4680-7
pubmed: 20534435
Curr Infect Dis Rep. 2010 Nov;12(6):417-22
pubmed: 21308549
Biomark Insights. 2007 Feb 07;1:215-25
pubmed: 19690652
PLoS Pathog. 2020 Jun 4;16(6):e1008524
pubmed: 32497113
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Dec;61(12):1528-1535
pubmed: 30397722
Clin Microbiol Infect. 2015 Jul;21(7):674.e1-9
pubmed: 25752224
Sci Rep. 2020 Jun 16;10(1):9720
pubmed: 32546712
Folia Biol (Krakow). 2014;62(1):73-8
pubmed: 24745152
BMJ. 2008 Oct 13;337:a1754
pubmed: 18852164
Clin Microbiol Infect. 2015 Sep;21(9):817-26
pubmed: 25936581
Indian J Med Microbiol. 2015 Apr-Jun;33(2):205-14
pubmed: 25865969
PLoS One. 2011;6(11):e26602
pubmed: 22073175
Sci Rep. 2015 Nov 17;5:16865
pubmed: 26574055
J Clin Microbiol. 2011 Jul;49(7):2643-50
pubmed: 21525231
PLoS One. 2014 Aug 22;9(8):e105998
pubmed: 25148517
J Clin Microbiol. 2010 Aug;48(8):2779-85
pubmed: 20573862
CA Cancer J Clin. 2017 Jul 8;67(4):326-344
pubmed: 28481406
Nature. 2007 Oct 18;449(7164):804-10
pubmed: 17943116
PLoS Comput Biol. 2021 Nov 8;17(11):e1009581
pubmed: 34748542
Pathol Annu. 1973;8:301-28
pubmed: 4583016
J Infect Dis. 1999 Dec;180(6):1863-8
pubmed: 10558942
Nat Rev Urol. 2020 Apr;17(4):232-250
pubmed: 32071434
PLoS One. 2016 Apr 26;11(4):e0153274
pubmed: 27115350
Int J Cancer. 2014 Sep 15;135(6):1408-16
pubmed: 24519782
Cell Host Microbe. 2013 Aug 14;14(2):207-15
pubmed: 23954159
mSphere. 2020 Nov 18;5(6):
pubmed: 33208514
Lancet Oncol. 2010 Mar;11(3):249-57
pubmed: 20089449
BJOG. 2020 Jan;127(2):139-146
pubmed: 31597208
Microbiome. 2018 May 17;6(1):90
pubmed: 29773078
Cancers (Basel). 2019 Mar 05;11(3):
pubmed: 30841606
Cancer Med. 2018 May;7(5):2172-2179
pubmed: 29608253
Lancet Oncol. 2012 Jan;13(1):78-88
pubmed: 22177579
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Appl Environ Microbiol. 2008 Apr;74(8):2461-70
pubmed: 18296538
Cell. 2016 Jan 28;164(3):337-40
pubmed: 26824647
Obstet Gynecol. 2010 Feb;115(2 Pt 1):243-248
pubmed: 20093895